A Personalized Cancer Immunotherapy Paradigm: simple solutions to address complex options for patients
Priti Hedge, PhD Genentech
Priti Hedge, PhD Director
Senior Scientist
Genentech
Dr Priti Hegde is a Director and Senior Scientist at Genentech where she leads biomarker discovery and development for cancer immunotherapy programs including atezolizumab in addition to the Avastin franchise. Her group is focused on both understanding cancer disease biology as it pertains to the tumor microenvironment as well as studying the clinical mechanism of action of therapeutics. Identification of mechanism based predictive biomarkers and development of diagnostic strategies for clinical development of cancer immunotherapy agents is also a strong focus of her group. Prior to joining Genentech in 2007, Priti led the biomarker discovery efforts for Oncology and cardiovascular diseases at GSK. Priti received her Postdoctoral training in human
genomics from The Institute for Genomics Research (TIGR) in 2000 and her PhD in biochemical pharmacology from SUNY Buffalo in 1997.
